Julia Aijun Wang - Jul 1, 2022 Form 4/A - Amendment Insider Report for BeiGene, Ltd. (BGNE)

Role
Chief Financial Officer
Signature
/s/ Qing Nian, as Attorney-in-Fact
Stock symbol
BGNE
Transactions as of
Jul 1, 2022
Transactions value $
-$50,245
Form type
4/A - Amendment
Date filed
7/18/2022, 05:22 PM
Date Of Original Report
Jul 5, 2022
Previous filing
Jun 24, 2022
Next filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BGNE American Depositary Shares Sale -$50.2K -317 -100% $158.50 0 Jul 1, 2022 Direct F1, F2, F3
holding BGNE Ordinary Shares 241K Jul 1, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The original Form 4, filed on July 5, 2022, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a sale that occurred on July 1, 2022 as a total of 295 American Depositary Shares ("ADSs") sold when in fact 317 ADSs were sold. As a result of this administrative error, the number of Ordinary Shares beneficially owned by the reporting person following the corrected transaction reflects a reduction in the number of Ordinary Shares reported as beneficially owned by the reporting person by 286 Ordinary Shares.
F2 Each American Depositary Share represents 13 Ordinary Shares.
F3 The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.